Gemcitabine Hydrochloride Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable is a white to off-white crystalline powder with an anhydrous molecular weight of 299.66 g/mol and the molecular formula C9H11F2N3O4·HCl. The CAS registry number is 122111-03-9. The hydrochloride salt is the pharmaceutical starting material for lyophilised injection vials, oral capsules, tablets, and granules; the free base has an anhydrous molecular weight of 263.20 g/mol and is not ordinarily used as a finished-dosage-form input because of limited aqueous solubility. The salt formation adds 36.46 g/mol of hydrogen chloride and provides the solubility required for parenteral compounding and for aqueous granulation in solid oral processing.

The pharma grade is released against a specification derived from the relevant gemcitabine hydrochloride monographs and from ICH Q3C, ICH Q3D, and current good manufacturing practice controls under 21 CFR 211. Final selection of particle size, residual solvent profile, and endotoxin load depends on whether the API enters a sterile injectable line or a solid oral dosage line. The same chemical entity can support both routes, but injectable manufacture requires a low-bioburden input, a validated pyrogen-control strategy, and container closure integrity data generated under ICH Q1A conditions. Oral tablet and capsule manufacture requires a defined particle size distribution and moisture control to prevent cohesion and content uniformity drift; granulation is typically required because the untreated powder may exhibit poor flow and high fines content.

What Release Limits and Pharmacopoeial Methods Are Applied to Injectable-Use Gemcitabine Hydrochloride?

Because injectable-grade API enters a sterile manufacturing train rather than a terminal tableting process, the compendial and dossier release specification includes tests that are less critical for solid oral grades. The following matrix represents a typical compliance profile assembled from USP–NF and Ph. Eur. monographs for gemcitabine hydrochloride, ICH Q3D, and ICH Q3C.

The limits shown are not universal; the marketing authorisation dossier may impose tighter internal release limits. A parenteral marketing authorisation may require a specific endotoxin limit derived from the maximum adult single dose according to USP <85>, while an oral solid dosage dossier may not include an endotoxin limit at all. The certificate of analysis should be reconciled against the approved specification, the supplier’s process validation report, and the receiving site’s incoming material procedure.

As a crystalline powder with a defined but often fine particle fraction, gemcitabine hydrochloride can segregate in high-speed capsule filling and rotary tablet compression. The particle size distribution is typically measured by laser diffraction under USP <429> or ISO 13320:2020; release and stability lots are characterised by d10, d50, and d90 values. For low-dose oral solid dosage forms, a d90 below 100 µm can support content uniformity after geometric dilution, but the same fine fraction may create poor flow, static build-up, and sticking on tablet punches. Production-scale batch records therefore specify a granulation step before compression: wet granulation in a high-shear mixer or fluid bed, or dry granulation via roller compaction. During aqueous wet granulation, the binder vehicle is maintained in an acidic range because gemcitabine hydrochloride is susceptible to accelerated degradation at alkaline pH. For injectable manufacture, the reconstituted solution is typically pH-adjusted to 2.7–3.3 to minimise deamination and glycosidic hydrolysis. Dry granulation via roller compaction can mitigate the compaction defects seen with fine crystalline fractions; twin-screw granulation may be evaluated, but published data for this specific formulation configuration is limited.

For lyophilised injection vials, particle size of the API is not the primary release concern; instead, bacterial endotoxins, bioburden, particulate matter after reconstitution, and cake appearance are controlled at the drug product stage. The API is dissolved, the solution is sterilised by filtration, and the product is lyophilised; API crystal habit does not govern final product quality as long as dissolution is complete and filter integrity is demonstrated. A low-bioburden API reduces the challenge to the sterilising filter and is therefore normally specified for injectable use.

Residual Solvent, Polymorph, and Elemental Impurity Control Boundaries in the Hydrochloride Salt

Residual solvent compliance is established under ICH Q3C and not from a single pharmacopoeial value. The synthetic route determines which Class 2 and Class 3 solvents must be monitored; headspace gas chromatography under USP <467> or Ph. Eur. 2.4.24 is used for release. Class 1 solvents such as benzene and carbon tetrachloride are controlled at the corresponding ICH Q3C limits and are verified when the supplier’s route documentation indicates their use. Elemental impurity control follows ICH Q3D Option 1 or an equivalent risk assessment; residual palladium or nickel from hydrogenation catalysts must be addressed because the hydrochloride salt itself does not introduce a metallic counterion. Plasma-based detection by ICP-MS or ICP-OES under USP <233> is the usual finish; the limit is based on the permitted daily exposure for the intended route of administration, with parenteral routes generally imposing tighter PDE-derived limits than oral routes.

Polymorphic identity is confirmed by X-ray powder diffraction and differential scanning calorimetry. Micronization or dry milling operations can introduce amorphous content; if the particle size specification requires aggressive size reduction, the manufacturer should add an amorphous-content or crystallinity check because amorphous domains can change moisture uptake and dissolution behaviour. The dry API is stable under protected storage, but open handling at relative humidity greater than 60% can produce surface water uptake and caking; pre-drying and humidity-controlled suites are recommended for moisture-sensitive formulations. The approved container closure system is selected to maintain water content through retest and is validated under ICH Q1A or ICH Q1B conditions. Aqueous solutions are not stockpiled; they are prepared immediately before downstream processing and maintained under acidic pH. Published data on long-term high-humidity processing beyond the manufacturer’s storage statement is limited.

Route-specific differences in release specification for the same hydrochloride salt are summarised below.

When compared with gemcitabine free base, the hydrochloride salt offers the required aqueous solubility for injectable formulation and for wet granulation. The molecular weight correction of 36.46 g/mol between the free base and the salt must be applied in certificate-of-analysis review and in label claim calculations; an assay result expressed on an anhydrous basis can otherwise be misinterpreted when the salt factor is omitted. The free base is largely a synthetic intermediate and research material, whereas the hydrochloride is the compendial entity used in finished dosage forms. Other salt forms and co-crystals are not established in the major pharmacopoeias; published data for their use in oral or injectable gemcitabine products is limited. Differences from other cytidine analogues such as cytarabine arise from the 2′,2′-difluoro substitution on the ribose ring, which alters the hydrolysis profile and requires the acidic handling environment described above. The term “oral and injectable” in the product designation refers to the applicability of the same API to both routes after route-specific release controls are applied, not to the interchangeability of the final dosage forms without process validation.